The company, which specializes in drug delivery for a portfolio of polymer delivery vehicles used in skin care and dermatological products, says that its latest patent is aimed specifically at the protection of the polymer composition for the delivery system.
The company claims that when the ingredient is topically applied, it holds active ingredients on the skin for up to four hours. This process gives the active ingredients an extended timeframe to perform intended functions, consequently increasing a products efficacy.
The prrevious patent for Invisicare was issued to the company for the 'Method of Manufacturing' the product. The company says that a third patent application, related to 'Methods of Use' for the formulation is currently pending.
Skinvisible CEO Terry Howlett said that the patent would enable the company to protect the mechanisms used by the formulation that enable the skin to cling on to skin care formulations for long periods of time.
Howlett also noted that the formulation would mean "longer duration of action, reduced irritation and lower dosage of active agent required."
These functions should go a long way to creating better skin care products as well as enabling producers to save money on lower doses of more expensive active ingredients.
Last week Skinvisible announced claims that a hand sanitizer it manufactures can be used to cut the risk of spreading bird flu through skin contact.
The company said that a virology study carried out by research scientists at Queen Mary College, University of London, proves that the company's chlorohexidine hand sanitizer has a greater than 99 per cent kill on the bird flu virus.